Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (207)	1/16/2003 10:58:01 AM
From: tuck	Read Replies (1) \| Respond to of 3722

Looking at this chart (edit: or one using this ticker with your own parameters) and knowing that the recent little gap down is due to announcement of a secondary, would folks here buy this or sell it? siliconinvestor.com TIA & Cheers, Tuck

To: Jibacoa who wrote (207)	1/16/2003 11:17:16 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

IDPH Has now fully closed its November 26 down-gap. The stock has been up 11% today after DNA reported that its 4th Qnet more than doubled thanks in part to increased sales of Rituxan Rituxan is IDPH's human monoclonal antibody designed to help the patient's own immune system destroy normal and malignant B cells and was approved by the FDA in November 1997 for the treatment of NHLs. IDPH also sells Rituxan outside the US under the name MabThera. siliconinvestor.com siliconinvestor.com Bernard